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Abstract
Background: Opioid maintenance treatment (OMT) has a positive impact on substance use and health outcomes
among HIV-infected opioid dependent patients. The present study investigates non-medical use of opioids by HIV-
infected opioid-dependent individuals treated with buprenorphine or methadone.
Methods: The MANIF 2000 study is a longitudinal study that enrolled a cohort of 476 HIV-infected opioid-dependent
individuals. Data were collected in outpatient hospital services delivering HIV care in France. The sample comprised
all patients receiving OMT (either methadone or buprenorphine) who attended at least one follow-up visit with data
on adherence to OMT (N = 235 patients, 1056 visits). Non-medical use of opioids during OMT was defined as having
reported use of opioids in a non-medical context, and/or the misuse of the prescribed oral OMT by an inappropriate
route of administration (injection or sniffing). After adjusting for the non-random assignment of OMT type, a model
based on GEE was then used to identify predictors of non-medical use of opioids.
Results: Among the 235 patients, 144 (61.3%) and 91 (38.9%) patients were receiving buprenorphine and
methadone, respectively, at baseline. Non-medical use of opioids was found in 41.6% of visits for 83% of individual
patients. In the multivariate analysis, predictors of non-medical use of opioids were: cocaine, daily cannabis, and
benzodiazepine use, experience of opioid withdrawal symptoms, and less time since OMT initiation.
Conclusions: Non-medical use of opioids was found to be comparable in OMT patients receiving methadone or
buprenorphine. The presence of opioid withdrawal symptoms was a determinant of non-medical use of opioids
and may serve as a clinical indicator of inadequate dosage, medication, or type of follow-up. Sustainability and
continuity of care with adequate monitoring of withdrawal symptoms and polydrug use may contribute to
reduced harms from ongoing non-medical use of opioids.
Keywords: opioid maintenance treatment, buprenorphine, methadone, non-medical use, HIV, withdrawal,
antiretrovirals
Background
Among HIV-infected opioid dependent individuals, the
clinical management of drug dependence is a matter of
great concern. This issue is especially relevant in those
countries where the HIV epidemic is driven by injecting
drug users (IDUs) [1,2]. Even in industrialized countries,
HIV-infected opioid-dependent persons seeking care for
their drug dependence may face many barriers to effec-
tive treatment, and their management may be compli-
cated by the difficulties associated with the provision of
multiple treatments [3]. Opioid maintenance treatment
(OMT) has been found to reduce high risk behaviors
related to HIV transmission such as injecting drugs,
sharing needles/syringes, and having unprotected sex
[4]. In France, two forms of OMT, with buprenorphine
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treatments has been found to have a substantial benefi-
cial impact upon the growth of the HIV epidemic [5].
The initiation of OMT with methadone or buprenor-
phine in HIV-infected opioid dependent patients has
been found to have a positive impact on health out-
c o m e s[ 6 ] ,a n dp l a y sa ni m p o r t a n tr o l ei ns u s t a i n i n g
adherence to antiretroviral treatment (ART) for HIV
infection [7]. The topic of adherence to ART has been
widely studied since the beginning of the HIV epidemic
[8]. In injecting drug users (IDUs) [9], adherence to
ART is important because sub-optimal adherence to
ART may lead to the risk of HIV resistance and acceler-
ated progression of disease [10]. In this paper, we
focused on non-medical use of opioids defined as either
use of illicit opioids such as heroin or other non-pre-
scribed opioids, or use of OMT (buprenorphine or
methadone) by a non medically prescribed route of
administration. Non-medical use of opioids, especially
by injection, is particularly relevant in HIV-positive
patients because it is a major correlate not only of
response to OMT but also to antiretroviral therapy
response as expressed by non-adherence [7] and virolo-
gical failure [11].
The MANIF 2000 cohort study took place in several
settings in France and was designed to focus on socio-
behavioral aspects of HIV-positive IDUs, with particular
emphasis on their access and adherence to antiretroviral
treatment as well as OMT-related outcomes. The inclu-
sion of HIV-infected opioid-dependent individuals, while
buprenorphine and methadone were launched to treat
opioid drug dependence, provided us with the opportu-
nity to identify the correlates of non-medical use of
opioids during opioid maintenance treatment.
Methods
Cohort and sample
The French MANIF 2000 cohort in 1995/1996 enrolled
467 patients who were HIV-positive. Inclusion criteria
for enrollment in the cohort were: receiving OMT treat-
ment, patients with a CD4+ cell count > 300 during the
last visit prior to enrolment and in clinical stage A or B.
This cohort was designed to focus on social and beha-
vioral aspects of HIV-positive IDUs and particularly on
their access [12] and adherence to antiretroviral treat-
ment [13] as well as to OMT [14]. In this study, we only
selected visits during time periods when patients were
enrolled in OMT, either methadone or buprenorphine,
and had available data on opioid use, including OMT.
The sample comprised 235 individuals, accounting for a
total of 1056 visits. All individuals who agreed to be
interviewed signed an informed consent form, approved
with the study protocol by the Committee for the Protec-
tion of Persons (CPP) involved in biomedical research.
Data collection
Data were collected at 6-month intervals by means of a
face-to-face interview, a self-administered questionnaire,
and medical records. The face-to-face interview was
based on a standardized protocol, administered by
trained nurses, which gathered psychosocial information
and patients’ personal experience with HIV infection
and care. The self-administered questionnaire included
socio-demographic data, prison history, substance use
and related behaviours, OMT exposure (methadone or
buprenorphine), and consumption of psychotropic drugs
and alcohol during the previous 6 months. Self-reported
use of heroin and morphine were checked for validity at
enrollment by morphine detection in urine samples.
Injection drug use at any given visit thereafter was
defined as the injection of any drug in the 6 months
before that visit.
Clinical and laboratory data on viral load, CD4 T-cell
counts and data on HIV clinical stage, with stage C indi-
cating progression to AIDS disease were collected every
6 months from the physician or from medical records
[15]. An undetectable viral load was defined as an HIV-
1 RNA level below the lower limit of detection of the
assay and was considered a virological success. Informa-
tion was also collected about the first positive HIV test
and patients’ ART history.
Depression was measured using the French version of
the Center for Epidemiological Studies Depression Scale
(CES-D) [16]. The 75th percentile (age-gender specific)
of the distribution of values for the corresponding indi-
cator in the general French population was used to clas-
sify patients as depressed or not depressed at each
interview. Then, the CES-D score was dichotomized by
using 17 and 23 as cut-off points for men and women,
respectively, as indicative of depression, on a score scale
ranging from 0 to 60, as already validated in a previous
study [17].
Involvement with “non-medical use of opioids” was
collected through both patients’ and physicians’ answers
to the questionnaires. There was little discrepancy
between physicians’ and patients’ reports about OMT: in
cases of disagreement, patients’ self reports were consid-
ered as more reliable and were used in the analyses. At
any given visit, time since OMT initiation was computed
as the uninterrupted time-interval between the last
initiation or re-initiation of OMT until that visit. Also,
the prescribed dose of OMT was considered low if the
methadone dose was less than 60 mg per day or the
buprenorphine dose was less than 8 mg per day.
Information about the use of opioids and OMT was
collected by means of the self-administered question-
naire and the structured face-to-face interview. Non-
medical use of opioids was defined as use of illicit or
non-prescribed opioids, and/or the misuse of the
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drug administration. Specifically, individuals were con-
sidered as having non-medical use of opioids if at any
given visit they reported use of any opioid drug other
than their prescribed OMT medication, or if they
reported having administered their prescribed OMT by
sniffing or injection in the previous 6 months.
Statistical analysis
A 2-step Heckman approach allowed us to account for
the non-random assignment to different types of OMT
medication. The first step, explained in a previous paper
[18], was based on a probit model to identify predictors
of starting either buprenorphine or methadone treat-
ment and led to the computation of the inverse Mills
ratio (IMR). The IMR was then introduced in the sec-
ond step model to correct for the potential non-random
assignment of buprenorphine and methadone (prescrip-
tion bias).
A model based on Generalized Estimating Equations
(GEE) was then used to identify predictors of non-medi-
cal use of opioids while correcting for the bias induced
by non-random assignment. Variables with p-values <
0.20 in the univariate analysis of each step were consid-
ered eligible for inclusion in the multivariate models. An
exchangeable correlation matrix was used for the GEE
models. All variables tested, including the IMR, were
considered eligible to enter the model. A backward pro-
cedure was used to identify the best GEE model and
variables were removed one at a time based on a p-
value > 0.05. The log-likelihood ratio test was used to
identify the best pattern of predictors. Bias-corrected
confidence intervals and p-values were based on 400
bootstrap replications.
Results
Descriptive results at baseline
Among the 235 patients, 163 (69.4%) were men and
72 (30.6%) were women. The median [IQR] age was
34 [31-37] years. Thirty-four (14.8%) patients had a
high school certificate and 150 (63.8%) were the
o w n e ro rr e n t e ro ft h e i ra c commodation. Depressive
symptoms were found in 170 (73%) patients. Use of
cocaine was reported by 85 (36.5%) and heroin use by
141 (60.5%). One hundred and forty eight (63%)
patients reported having injected any drug in the 6
months before the first visit on OMT. Heavy drinking
was reported by 57 (24.9%) patients. Buprenorphine
was the more commonly prescribed type of medica-
tion: this was prescribed to 144 (61.3%) patients at
baseline, with 91 (38.9%) receiving methadone. About
one fifth of the patients (n = 46, 19.6%) were being
treated with ART.
Descriptive results during the study period
The descriptive analysis of the whole study period is
presented in Table 1.
During the study period, the median [IQR] time since
the initiation of opioid maintenance treatment was 16
[13-20] months. Among the 235 patients, 18 switched
from buprenorphine to methadone, 10 switched from
methadone to buprenorphine, and one switched from
buprenorphine to methadone and then back to bupre-
norphine. Among all the treatment visits, non-medical
use of opioids was found in 439 (41.6%) visits for 196
individual patients. In addition, the mean duration of
study follow-up for our sample was 45 months.
First step: Predictors of OMT prescription, buprenorphine
or methadone
In the first step model, factors independently associated
with methadone prescription were unemployment,
drinking more than 4 units of alcohol per day, cocaine
use in the 6 months prior to the visit, and smoking
more than 20 cigarettes per day [18].
Second step: Univariate and multivariate analyses
The results of the univariate analysis are presented in
Table 1. No statistically significant difference was found
between type of maintenance medication (buprenor-
phine or methadone) with regard to non-medical use of
opioids, after correcting for the bias induced by non-
random assignment. Regarding HIV status, a number of
variables were found to be associated with non-medical
use of opioids in the univariate but not in the multivari-
ate analyses: not receiving ART, being at clinical stage A
(compared to B and C), having a higher duration since
first testing positive for HIV, not having an undetectable
viral charge and not reporting having a complete trust
in the physician. Socio-demographic factors that were
found to be associated with non-medical use of opioids
included younger age, and not being owner or renter of
his/her accommodation. Patients who reported depres-
sive symptoms were more likely to have reported non-
medical use of opioids. Lower doses of OMT were not
significantly associated with non-medical use of opioids.
I nt h em u l t i v a r i a t ea n a l y s i sp r e s e n t e di nT a b l e2f i v e
variables that were found to be significant in the uni-
variate analysis remained significantly associated with
the outcome. These included non-opioid drug use (use
of cocaine and benzodiazepines, and daily use of canna-
bis). Patients who reported having experienced opioid
withdrawal symptoms in the 6 months prior to the visit
were found to report more non-medical use of opioids.
Uninterrupted attendance at an OMT program until a
given visit was associated with less non-medical use of
opioids.
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Non-medical use of opioids was found to be comparable
in HIV-infected opioid dependent patients receiving
methadone or buprenorphine. In addition, our results
showed that ongoing use of non-opioids (such as
cocaine, cannabis, and benzodiazepines), perception of
withdrawal symptoms, and a shorter retention in OMT
are associated with non-medical use of opioids. At a
time when non-medical use of prescription opioids [19]
and use of opioids by injection [20-22] are growing pro-
blems and a real concern for public health, identifying
correlates of non-medical use of opioids is of interest
and should help physicians to better manage opioid
dependence and improve the effectiveness of OMT in
not only HIV-infected population but also the whole
population of opioid-dependent individuals.
First, it is interesting to note that, according to the
results of the univariate analysis, HIV care has a positive
impact on decreasing non-medical use of opioids.
Patients who were receiving antiretroviral treatment
(ART) were less likely to report non-medical use of
opioids. This result may be related to the wider access
to ART in IDUs who achieved stabilization on OMT
Table 1 Factors associated with non-medical use of opioids during opioid maintenance treatment: univariate analyses.
Number of visits
(%) or median [IQR]
Nb. of patients Coefficient
(95% CI)
p-value
Buprenorphine (ref) 640 (60.6) 154
Methadone 416 (39.4) 111 0.00 (-0.41; 0.37) 0.98
Female gender 286 (27.1) 72 0.16 (-0.09; 0.39) 0.20
Age
a 36 [32-39] -0.69 (-0.96; -0.43) < 10
-3
Owner or renter of their house 757 (71.7) 189 -0.24 (-0.45; 0.00) 0.03
Good housing conditions
b 868 (82.4) 210 -0.13 (-0.39; 0.08) 0.22
Heavy drinking
c 213 (20.4) 95 0.15 (-0.07; 0.40) 0.20
Cocaine use
d 277 (26.3) 115 0.91 (0.67; 1.20) < 10
-3
Cannabis use (daily)
d 467 (44.4) 156 0.45 (0.29; 0.62) < 10
-3
Benzodiazepine consumption
d 358 (33.9) 150 0.62 (0.44; 0.81) < 10
-3
HIV clinical stage
A (ref) 474 (44.9) 138
B 518 (49.1) 125 -0.24 (-0.49; -0.01) 0.06
C 63 (6.0) 22 -0.68 (-1.17; -0.28) 0.003
Depressive symptoms
e 666 (63.2) 200 0.34 (0.18; 0.52) < 10
-3
Withdrawal symptoms 204 (19.3) 122 0.81 (0.56; 1.07) < 10
-3
Time since first injection (years)
a 16 [13-20] -0.56 (-0.86; -0.32) < 10
-3
Time since first positive HIV test (years)
a 11 [8-13] -1.00 (-1.35; -0.76) < 10
-3
Time since OMT initiation (months)
f 16 [7-30] -0.29 (-0.39; -0.22) < 10
-3
Undetectable viral charge 366 (34.9) 124 -0.25 (-0.46; -0.03) 0.03
CD4 cell count/mm
3 < 200 57 (5.5) 32 -0.26 (-0.65; 0.15) 0.20
Receiving ART 395 (37.4) 119 -0.52 (-0.70; -0.30) < 10
-3
Complete trust in physicians 824 (78.4) 196 -0.33 (-0.62; 0.10) 0.01
Low prescribed dose of OMT
g 676 (66.8) 169 -0.22 (-0.43;0.04) 0.06
*MANIF 2000 cohort, N = 235, 1056 visits.
a For ten years increase.
b Good housing conditions were defined as the rank 3 and 4 (quite or very comfortable vs. uncomfortable or low comfort) using a four-point Likert scale.
c Heavy drinking was defined as drinking more than 4 alcohol units on any one occasion.
d During the previous 6 months.
e Patients were defined with depressive symptoms if CES-D > 17 for men and > 23 for women.
f For one year increase.
gPrescribed dose of OMT is low if the methadone dose was less than 60 mg per day or the buprenorphine dose was less than 8 mg per day.
Table 2 Factors associated with non-medical use of
opioids during opioid maintenance treatment:
multivariate analysis.
Adjusted coefficient
(95% CI)
p-value
Cocaine use
d 0.81 (0.57; 1.10) < 10
-3
Cannabis use (daily)
d 0.28 (0.08; 0.47) 0.01
Benzodiazepines consumption
d 0.37 (0.16; 0.55) < 10
-3
Withdrawal symptoms 0.62 (0.36; 0.89) < 10
-3
Time since OMT initiation (months)
f -0.25(-0.35;-0.18) < 10
-3
d During the previous 6 months.
f For one year increase.
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positive impact on drug injecting cessation in HIV-
infected IDUs [24]. This impact could be explained by
the reality of the relationship between physician and
patient based upon trust in the ART initiation process
[25], as suggested in our univariate analysis. This latter
result supports the idea that access to ART in HIV-
infected opioid dependent individuals could play a harm
reduction role.
However, the results of the multivariate analysis show
the most important predictors of non-medical use of
opioids which are not related to HIV care in our analysis.
And after multiple adjustments (including for non ran-
dom assignment of buprenorphine and methadone), only
shorter time since OMT initiation, experience of withdra-
wal symptoms, and non-opioid drug use were found to
be significant determinants of non-medical use of opioids.
Among the independent predictors of non-medical use of
opioids, some patients’ illicit substance use behaviors
such as cocaine, daily cannabis, and benzodiazepine use
were associated with the outcome. These findings are
consistent with those of previous studies showing that
non-opioid drug use in OMT-treated patients may nega-
tively influence treatment outcomes. For instance, cocaine
use during OMT has previously been shown to be a pre-
dictor of buprenorphine diversion by injection in patients
receiving prescribed buprenorphine [14] and to hinder
efficacy of OMT [26]. In addition, OMT patients who
had used benzodiazepines were more likely to have
opioid-positive urine screens during OMT [27]. This is a
concern because few guidelines are available to physicians
who are required to treat co-dependent drug users. A
recent meta-analysis has summarized the most common
approaches to treating benzodiazepine dependence [28]
and the most effective is a combination of a gradual dose
reduction regimen and psychological interventions. More-
over, a recent study showed that opioid dependent indivi-
duals receiving heroin-assisted treatment were more
likely to decrease their benzodiazepine use compared to
those receiving methadone maintenance treatment [29].
Finally, heavy cannabis use also has been found to be
correlated with buprenorphine injection [30]. Polydrug
use should be considered more thoroughly not only for
measuring the independent effects of multiple drug use
but also for investigating the effects of drug use patterns
on behavioural outcomes [31].
Although the association between time since OMT
initiation and non-medical use of opioids is not unex-
pected, it demonstrates that the longer the duration of
OMT (retention in OMT), the better achievement of
stabilization in terms of heroin use and OMT diversion
[32]. The clinical management of opioid dependence has
already been described as a very long process with a
high risk of cycling in and out of treatment [33].
Patients who reported withdrawal symptoms during
the study period were also found to report higher non-
medical use of opioids. This result is clinically very rele-
vant and suggests that physicians should investigate sub-
jective and objective withdrawal symptoms during
treatment in order to better understand the reasons that
inter-dose opioid withdrawal exist [34]. Their occur-
rence may be indicative of inadequate OMT dosage
[35,36], either too low, which leads to withdrawal symp-
toms directly, or too high, which leads to aversive side
effects that lead to discontinuation of OMT. However,
the results do not support the notion that lower doses
of OMT are related to more non-medical use of opioids,
probably because low doses were a proxy for less severe
opioid dependence and not for inadequate dose pre-
scription. Other factors could be related to disliking of
the subjective effects of OMT, or polydrug use, which
also may lead patients to interrupt treatment [37,38].
This issue is all more relevant since Mateu-Gelabert et
al showed that withdrawal symptoms could increase
risky behaviors regarding HIV and also Hepatitis C virus
(HCV) transmission by undermining IDUs’ willingness
to inject safely [39].
Recent WHO guidelines recommend that the dose of
OMT should be increased progressively according to
clinical effect in the individual patient, up to an ade-
quate dosage [40]. In addition, drug interactions repre-
sent a potential concern in HIV-infected individuals,
especially with regard to methadone and protease inhibi-
tors, and in these circumstances, methadone dose
adjustments may be required to avoid withdrawal symp-
toms [41]. In addition, the experience of withdrawal
symptoms among HIV-infected patients who are receiv-
ing OMT needs careful surveillance and clinical man-
agement since the presence of withdrawal symptoms has
been associated with an increased risk of mortality in
the same cohort [42].
After adjustment for non-random allocation to bupre-
norphine/methadone prescription, we found no differ-
ence between methadone and buprenorphine with
regard to non-medical use of opioids. These findings are
consistent with previous studies showing that metha-
done and buprenorphine are broadly equivalent at
higher dosages [43]. The correction for the bias elicited
by non-random assignment was necessary due to the
two different models of OMT delivery in France which
may lead to the selection of different opioid drug depen-
dent populations. Historically, in France, initiation of
methadone is possible only in specialized centers for
drug dependence while access to buprenorphine is avail-
able in primary care settings [5]. This differential access
could explain why methadone in France is more fre-
quently initiated in patients presenting a severe addictive
profile. In France, methadone programs provide
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ered through primary care settings, which have minimal
ancillary services. Previous research has shown that
retention in OMT is influenced by several in-treatment
variables such as occurrence of depressive symptoms,
social functioning [44] and trust in the physician [45].
Therefore, although more severely dependent patients
were included in the methadone group, it is not entirely
surprising that non-medical use of opioids did not differ
from the buprenorphine group in our study because the
methadone patients had access to more comprehensive
care [46].
Some limitations of this study should be acknowl-
edged. Data on substance use was based on self-reported
behaviors, which are often questioned due to possible
social desirability bias. However, the validity and reliabil-
ity of self-reports about active drug use have been estab-
lished in many studies that used similar methods for
collecting information about substance use behaviors
[47,48] as well as in a previous study with a sample of
HIV-infected patients in which substantial agreement
was documented between self-reported heroin use and
morphine detection in urine [49]. Our results do not
allow a clear inference about the direction of effects.
Although the study started some years ago, this cohort
remains a very interesting observational sample of
patients, especially for countries that have only recently
started to scale up antiretrovirals and OMT for opioid
dependent HIV-infected individuals. Finally, although a
statistical adjustment was made to allow for non-ran-
dom assignment to medication type, this study was not
a controlled clinical trial and further investigations are
required to confirm our findings.
Conclusions
The results of the present study contribute towards a
better understanding of the factors associated with non-
medical use of opioids, and may also have implications
for understanding adherence to anti-retroviral therapy
in HIV-infected opioid-dependent individuals. When
methadone and buprenorphine are effective in stabiliz-
ing opioid dependence, they can also improve health
and socio-economic outcomes in HIV positive IDUs
[50]. Clinically, these findings demonstrate the impor-
tant relationship between withdrawal symptoms in
OMT treated patients and positive response to medica-
tion. More generally, it emphasizes the importance of
being attentive to the provided care and to the environ-
ment of patients. These findings corroborate the idea
that stabilization on OMT is not only a patient problem
[51]. Our data suggest that some combined and novel
approaches are necessary to decrease the harms asso-
ciated with abuse or dependence on benzodiazepines,
cocaine, and/or cannabinoids, especially in HIV-infected
individuals. Clinical intervention studies aimed at opti-
mizing effectiveness of OMT in HIV-infected patients
are required to better understand the extent of a more
comprehensive approach combining attention to with-
drawal symptoms, and treatment for other drug depen-
dence. Programs with better patients retention can
improve adherence to ART and HIV outcomes in peo-
ple living with HIV. Further research on new medica-
tions and new interventions for co-dependence on
stimulants and/or benzodiazepines is required to
develop a more comprehensive and effective model of
care for such populations and to assure improved OMT
and HIV outcomes.
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